Brain Advance Access originally published online on July 1, 2006
Brain 2006 129(9):2241-2265; doi:10.1093/brain/awl150
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review Article |
A systematic review of prion therapeutics in experimental models
MRC Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, University College London Queen Square, London, UK
Correspondence to: John Collinge, MRC Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK E-mail: j.collinge{at}prion.ucl.ac.uk
Prion diseases are transmissible, invariably fatal, neurodegenerative diseases which include Creutzfeldt–Jakob disease (CJD) in humans and bovine spongiform encephalopathy and scrapie in animals. A large number of putative treatments have been studied in experimental models over the past 30 years, with at best modest disease-modifying effects. The arrival of variant CJD in the UK in the 1990s has intensified the search for effective therapeutic agents, using an increasing number of animal, cellular and in vitro models with some recent promising proof of principle studies. Here, for the first time, we present a comprehensive systematic, rather than selective, review of published data on experimental approaches to prion therapeutics to provide a scientific resource for informing future therapeutics research, both in laboratory models and in clinical studies.
Key Words: prion; Creutzfeldt–Jakob disease; transmissible spongiform encephalopathy; experimental models; therapeutics
Abbreviations: CJD, Creutzfeldt–Jakob disease; CR, congo red; dpi, days post infection; DS, dextran sulphate; GAG, glycosaminoglycans; HM, heparan mimicking; HPA-23, heteropolyanion-23; IC50, half-maximal inhibition concentration in vitro; i.c., intracerebral; i.c.v., intracerebralventricle; i.p., intraperitoneal; iv, intravenous; LRS, lymphoreticular system; PPS, pentosan polysulphate; PrP, prion protein; PrPC, cellular prion protein; PrPSc, disease-associated prion protein; PrPsen, protease-sensitive prion protein; PrPres, protease-resistant prion protein (as monitored by proteinase-K resistant PrP immunoreactivity); Prnp, prion protein gene; SAF, scrapie-associated fibril; sc, subcutaneous (peripheral)
Received January 6, 2006. Revised May 4, 2006. Accepted May 8, 2006.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C.-H. Song, H. Furuoka, C.-L. Kim, M. Ogino, A. Suzuki, R. Hasebe, and M. Horiuchi Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice J. Gen. Virol., June 1, 2008; 89(6): 1533 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Stewart, L. H.M. Rydzewska, G. F. Keogh, and R. S.G. Knight Systematic review of therapeutic interventions in human prion disease Neurology, April 8, 2008; 70(15): 1272 - 1281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Brown Transmissible spongiform encephalopathy in the 21st century: Neuroscience for the clinical neurologist Neurology, February 26, 2008; 70(9): 713 - 722. [Full Text] [PDF]
|
|
|
|
|
|
C. Riemer, M. Burwinkel, A. Schwarz, S. Gultner, S. W. F. Mok, I. Heise, N. Holtkamp, and M. Baier Evaluation of drugs for treatment of prion infections of the central nervous system J. Gen. Virol., February 1, 2008; 89(2): 594 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-P. Courageot, N. Daude, R. Nonno, S. Paquet, M. A. Di Bari, A. Le Dur, J. Chapuis, A. F. Hill, U. Agrimi, H. Laude, et al. A cell line infectible by prion strains from different species J. Gen. Virol., January 1, 2008; 89(1): 341 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cronier, V. Beringue, A. Bellon, J.-M. Peyrin, and H. Laude Prion Strain- and Species-Dependent Effects of Antiprion Molecules in Primary Neuronal Cultures J. Virol., December 15, 2007; 81(24): 13794 - 13800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kawasaki, K. Kawagoe, C.-j. Chen, K. Teruya, Y. Sakasegawa, and K. Doh-ura Orally Administered Amyloidophilic Compound Is Effective in Prolonging the Incubation Periods of Animals Cerebrally Infected with Prion Diseases in a Prion Strain-Dependent Manner J. Virol., December 1, 2007; 81(23): 12889 - 12898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghaemmaghami, P.-W. Phuan, B. Perkins, J. Ullman, B. C. H. May, F. E. Cohen, and S. B. Prusiner From the Cover: Cell division modulates prion accumulation in cultured cells PNAS, November 13, 2007; 104(46): 17971 - 17976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pani, C. Norfo, C. Abete, C. Mulas, M. Putzolu, S. Laconi, C. D. Orru, M. D. Cannas, S. Vascellari, P. La Colla, et al. Antiprion Activity of Cholesterol Esterification Modulators: a Comparative Study Using Ex Vivo Sheep Fibroblasts and Lymphocytes and Mouse Neuroblastoma Cell Lines Antimicrob. Agents Chemother., November 1, 2007; 51(11): 4141 - 4147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-W. Phuan, J. A. Zorn, J. Safar, K. Giles, S. B. Prusiner, F. E. Cohen, and B. C. H. May Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compounds J. Gen. Virol., April 1, 2007; 88(4): 1392 - 1401. [Abstract] [Full Text] [PDF]
|
|